Roy D. Baynes, Director at Travere Therapeutics (TVTX), executed the exercise and immediate sale of 4,500 shares, generating approximately $210,000, as reported in a recent SEC Form 4 filing. The shares were sold at a weighted average price of $46.65, while the market closed at $44.80 on May 5, 2026. This transaction represents a 10.71% reduction in Baynes’s direct holdings, leaving him with 37,500 shares.
This sale, conducted under a 10b5-1 plan established in November 2025, indicates a structured approach to liquidity rather than a reaction to current market conditions. Despite the significant gain from exercising options with an $18.27 strike price, the transaction reflects a broader trend of declining direct ownership by Baynes, which may raise questions about insider sentiment.
For investors, the key takeaway is that while this sale appears profitable, it should not be interpreted as a negative signal for Travere Therapeutics. Baynes’s remaining stake, valued at approximately $1.6 million, suggests continued confidence in the company’s future prospects.
Source: fool.com